The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Rory,
A time I think for explaining some of the business / finance issues surrounding AS leadership in 2024.
AS leaves a legacy that requires explanation.
CC has the platform to paint a broader picture of how the situation can be improved.
CLN reduction a priority for CC (I hope)
Comms improvement
I'm thinking CC has lined up / is lining up replacement board members.
Like new R&D head.
Like new comms team
Why not now the focus is Therapeutics in USA.
Thanks Wilson.
I found these Exmex - perhaps you might have seen something different.
https://caseboard.io/cases/?prod_caseboard_cases%5Bquery%5D=yourgene
2 Jan 2024 - RNS -
Steve Gibson - Appointment of CFO
Commenting, James Wakefield, Non-Executive Chairman, said: "We are delighted to welcome Steve as our CFO. He has impressed us with his financial and operational expertise and was instrumental in the acquisition of Yourgene Health plc as well as delivering the strategic changes to the Company over the last two years. The Board looks forward to working with him as we continue to execute our growth strategy."
IMO that's JW saying SG is his financial man, and LR will have to budget his plans accordingly, else SG will advise JW of overspend.
Https://hallellis.co.uk/summary-judgment-applications-defences/ - Thanks Neil.
'What is Summary Judgment?
Summary judgment is a court order - judgment - which brings litigation to an end early.
The legal proceedings are brought to an end when, at a hearing of a summary judgment application a court finds that the CLAIM or the DEFENCE:
has no real prospect of success, and
there is no other compelling reason why the case should be allowed to proceed to trial.
Courts say that summary judgment is:
designed to deal with cases that are not fit for trial at all: Lord Woolf in Swain v Hillman (1999), the Court of Appeal
The judgment avoids a close examination of all the evidence which might be produced at the usual end point of litigation, which is the trial.
The parties are saved significant time, expense, worry and the distraction of enduring the entire litigation process through to the trial. There is no point.'
+++
The court will also hear an application by the DHSC for summary judgment in relation to one aspect of its claim, as part of which the DHSC is seeking judgment.
If that one aspect is set aside by the court, what else is left in the DHSC armoury?
I'm wondering if it has ever occurred that the court decides the claimant's Summary Judgment application
is the case that has no real prospect of success, in which case settlement is early May.
How likely might that be?
As you say Alcibiades,
Bachovin, Tufts Medical School, and Avacta own the patents behind PRECISION.
All three need to be satisfied by any company assuming ownership of Avacta's patent rights on purchase of Avacta.
09.04.2024 - Christina Coughlin delivered this quote in an RNS, hitting the nail on the head.
"The proof-of-concept data presented today with AVA6000 suggest that the peptide drug conjugate drug class has several key advantages, particularly the tumor-specificity of the release of doxorubicin through targeting FAP and simplicity of the manufacturing process which results in significant savings in the cost of goods."
She is discussing a market disrupting platform, and BP have been waiting for the trial to mature before showing interest.
IMO the point in time when Avacta receives FDA Approval will possibly be the catalyst for a Takeover
Currently buying the dips, how long this opportunity lasts is unknown.
Moderators have deleted this this morning, wouldn't you say so Oz?
Worth repeating I'd say
Eliot Forster
“And the really cool thing about our technology and there is not many companies on the planet who have this and lots are saying we want it, is that we hit the barricade and the actual cancer cells themselves, both at the same time and that’s a very cool thing.”